STOCK TITAN

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) granted stock options and restricted stock units to new hires on November 16, 2026. The awards, made under Nasdaq Listing Rule 5635(c)(4), include options to buy 225,000 common shares and 9,000 restricted stock units.

The options have a 10-year term and a $27.93 exercise price per share, equal to the common stock’s closing price on the grant date. Both awards vest over four years, subject to continued employment or other service through the applicable vesting dates. The awards are governed by the 2026 Inducement Plan and applicable award agreements.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Options to buy 225,000 common shares at $27.93 per share could dilute existing holders if exercised.
  • Minor point. Forward-looking: it has not happened yet and may not happen.9,000 restricted stock units could dilute existing holders as they vest and settle in common shares.

Key Figures

Stock options granted: 225,000 shares RSUs granted: 9,000 shares Option exercise price: $27.93 per share +3 more
Stock options granted
225,000 shares
Inducement grants to newly hired employees
RSUs granted
9,000 shares
Inducement grants to newly hired employees
Option exercise price
$27.93 per share
Equal to the closing price on the Grant Date
Stock option term
Ten years
Term of the inducement stock options
Stock option vesting
Four-year period; 25% at the one-year anniversary, then 36 equal monthly installments
Subject to continued employee service
RSU vesting
Four equal installments over a four-year period
Subject to continued employee service

Historical Context

1 past event · Latest: Oct 16
1 event
  1. Oct 16

    inducement grants

    24h Move
    +7.5%

    Prior employee inducement awards were 74,900 RSUs vesting in four equal annual installments.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units
2 terms
non-qualified stock options financial
"granted non-qualified stock options to purchase an aggregate of 225,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
restricted stock units financial
"an aggregate of 9,000 restricted stock units of the Company’s common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 225,000 shares of the Company’s common stock (“Stock Options”) and an aggregate of 9,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

The Stock Options have a ten-year term and an exercise price per share of $27.93, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Stock Options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of each of the employees’ first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments. The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of November 15, 2027, November 15, 2028, November 15, 2029 and November 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Contacts:

Investors:
Argot Partners
Zenas@argotpartners.com

Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How large were Zenas BioPharma’s November 16, 2026 inducement grants?

Zenas granted new hires options to buy 225,000 common shares and 9,000 restricted stock units. The options have a ten-year term and an exercise price of $27.93 per share.

When do Zenas BioPharma’s November 16, 2026 inducement grants vest?

The options vest 25% after one year of employment, with the rest vesting in 36 equal monthly installments. The restricted stock units vest 25% on each of November 15, 2027, November 15, 2028, November 15, 2029 and November 15, 2030. Both awards require continued service through the applicable vesting dates.

Keep reading